يعرض 1 - 10 نتائج من 75 نتيجة بحث عن '"Conjugate--administration & dosage"', وقت الاستعلام: 0.89s تنقيح النتائج
  1. 1
    دورية أكاديمية

    المساهمون: Anticorps en thérapie et pathologie - Antibodies in Therapy and Pathology, Institut Pasteur Paris (IP)-Institut National de la Santé et de la Recherche Médicale (INSERM), Physiologie, physiopathologie et thérapeutique (ED 394), Sorbonne Université (SU), Neovacs S.A Paris, Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Neuropathologie expérimentale / Experimental neuropathology, Institut Pasteur Paris (IP)-Université Paris Cité (UPCité), University of North Carolina Chapel Hill (UNC), University of North Carolina System (UNC), E.C. is the recipient of a CIFRE Ph.D. fellowship. B.B. was supported partly by a stipend from the Pasteur—Paris University (PPU) International Ph.D. program, and a fellowship from the French “Fondation pour la Recherche Médicale FRM”. N.G. acknowledges funding from the European Research Council (ERC-2018-STG, No. 802041) and the INSERM ATIP-Avenir program, B.H.K. acknowledges funding from the National Institutes of Health (NIH) HL093735 and an Award from the American Asthma Foundation. L.L.R. acknowledges support from the ATIP-Avenir program, and P.B. from the European Research Council (ERC)–Seventh Framework Program (ERC-2013-CoG 616050). This work was supported by a grant from the French National Research Agency ANR-18-CE18-0023 “AllergyVACS”, NEOVACS, the Institut National de la Santé et de la Recherche Médicale (INSERM) and the Institut Pasteur., ANR-18-CE18-0023,AllergyVACS,Développement d'un vaccin thérapeutique pour les maladies allergiques(2018), European Project: 802041, European Project: 616050,EC:FP7:ERC,ERC-2013-CoG,MYELOSHOCK(2014)

    المصدر: ISSN: 2041-1723.

    العلاقة: info:eu-repo/semantics/altIdentifier/pmid/33976140; info:eu-repo/grantAgreement//802041/EU/ERC-2018-STG/; info:eu-repo/grantAgreement/EC/FP7/616050/EU/Role of myeloid cells, their mediators and their antibody receptors in allergic shock (anaphylaxis) using humanized mouse models and clinical samples/MYELOSHOCK; hal-03229636; https://hal.sorbonne-universite.fr/hal-03229636Test; https://hal.sorbonne-universite.fr/hal-03229636/documentTest; https://hal.sorbonne-universite.fr/hal-03229636/file/s41467-021-22834-5.pdfTest; PUBMED: 33976140; PUBMEDCENTRAL: PMC8113315

  2. 2
    دورية أكاديمية
  3. 3
    دورية أكاديمية
  4. 4
    دورية أكاديمية
  5. 5
    دورية أكاديمية
  6. 6
    دورية أكاديمية
  7. 7

    المساهمون: Medical oncology laboratory, AII - Cancer immunology, CCA - Cancer biology and immunology, VU University medical center

    المصدر: Vaccine, Vol. 36, No 21 (2018) pp. 3054-3060
    Huijbers, E J M, van Beijnum, J R, Lê, C T, Langman, S, Nowak-Sliwinska, P, Mayo, K H & Griffioen, A W 2018, ' An improved conjugate vaccine technology; induction of antibody responses to the tumor vasculature ', Vaccine, vol. 36, no. 21, pp. 3054-3060 . https://doi.org/10.1016/j.vaccine.2018.03.064Test
    Vaccine, 36(21), 3054-3060. Elsevier BV

  8. 8
    دورية أكاديمية
  9. 9
    دورية أكاديمية
  10. 10
    دورية أكاديمية

    المؤلفون: Gjersvik, P

    المصدر: Tidsskrift for Den Norske Laegeforening. 126(19):2554